| P2093 | author name string | Robert B Raffa | |
| | Ellen A Walker | |
| | John J Foley | |
| P2860 | cites work | In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties | Q24679694 |
| | Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy | Q28266030 |
| | Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy | Q28275971 |
| | Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors | Q28284027 |
| | Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer | Q80251094 |
| | Assessment of learning and memory using the autoshaping of operant responding in mice | Q81130927 |
| | Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat | Q81249270 |
| | Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of c | Q81535306 |
| | Cancer chemotherapy impairs contextual but not cue-specific fear memory | Q30438754 |
| | Effects of increment size and reinforcer volume on progressive ratio performance | Q34457278 |
| | Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients | Q34587999 |
| | Breast cancer chemotherapy-related cognitive dysfunction. | Q35047689 |
| | Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective. | Q35047693 |
| | Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy | Q35047700 |
| | Mild cognitive impairment: conceptual issues and structural and functional brain correlates | Q35059777 |
| | Candidate mechanisms for chemotherapy-induced cognitive changes | Q35898051 |
| | CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. | Q36023980 |
| | Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI | Q36368924 |
| | Optimizing combination chemotherapy by controlling drug ratios | Q36935063 |
| | Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. | Q37121868 |
| | Clinical pharmacokinetics of anti-metabolites. | Q40730222 |
| | Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review | Q40838786 |
| | Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy | Q41104016 |
| | Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study | Q42162266 |
| | Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function | Q43626067 |
| | Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine | Q43810706 |
| | Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients | Q44114761 |
| | Hippocampal brain amines in methotrexate-induced learning and memory deficit | Q44254470 |
| | Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice | Q45233292 |
| | Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. | Q46552885 |
| | Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice | Q46767789 |
| | Effects of biasing the location of stimulus presentation, and the muscarinic cholinergic receptor antagonist scopolamine, on performance of a 5-choice serial reaction time attention task in rats | Q46868373 |
| | Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. | Q46882528 |
| | Interactions of steroid, methotrexate, and radiation determine neurotoxicity in an animal model to study therapy for childhood leukemia | Q48181584 |
| | Role of 5-HT1-7 receptors in short- and long-term memory for an autoshaping task: intrahippocampal manipulations | Q48237154 |
| | The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice | Q48436186 |
| | Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. | Q48445517 |
| | Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. | Q48458292 |
| | Effects of scopolamine and hippocampal lesions on negative patterning discrimination performance in rats | Q48559944 |
| | Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only | Q48788321 |
| | Phencyclidine retards autoshaping at a dose which does not suppress the required response | Q49088837 |
| | Cognitive function in breast cancer patients receiving adjuvant chemotherapy. | Q51079423 |
| | Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. | Q51099382 |
| | Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. | Q51986288 |
| | Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. | Q52011881 |
| | An automated learning and memory model in mice: pharmacological and behavioral evaluation of an autoshaped response. | Q52036630 |
| | Studies on desglycinamide arginine vasopressin and scopolamine in a modified/lever-touch autoshaping model of learning/memory in rats. | Q52130668 |
| | Methotrexate does not interfere with an appetitive Pavlovian conditioning task in Sprague-Dawley rats. | Q52204989 |
| | An animal model to detect the neuropsychological toxicity of anticancer agents. | Q52248003 |
| | Progressive ratio as a measure of reward strength. | Q52357905 |
| | Cognitive Function, Fatigue, and Menopausal Symptoms in Women Receiving Adjuvant Chemotherapy for Breast Cancer | Q53365999 |
| | Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients | Q71175730 |
| | White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support | Q72847962 |
| | 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil | Q73258215 |
| | Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics | Q74061504 |
| P433 | issue | 4 | |
| P921 | main subject | fluorouracil | Q238512 |
| | methotrexate | Q422232 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 527-538 | |
| P577 | publication date | 2008-05-08 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory | |
| P478 | volume | 199 | |